The world’s most advanced malaria vaccine got the nod Friday, July 24, from European regulators, despite mixed trial results, for eventual use in children in African countries plagued by the killer disease.
Dubbed Mosquirix or RTS, the drug received a “positive scientific opinion” from the European Medicines Agency (EMA) following decades of research and millions of dollars of investment. But it has yet to pass a final World Health Organization (WHO) hurdle, and may not become available before 2017.
Agence France-Presse reports.
There are no comments yet. Add your comment to start the conversation.